Software That Decides: What CIOs and Compliance Officers Must Know Before Buying SaMD

As AI-driven clinical tools multiply faster than regulatory frameworks can track them, the procurement decisions made today will shape both patient safety outcomes and your organization's legal exposure for years to come.

Why this matters

Picture this: a health system purchases an AI-powered chest X-ray triage tool marketed as helping radiologists prioritize urgent reads. The vendor's sales team demonstrates impressive sensitivity statistics and mentions the product has "FDA clearance." The system goes live. Twelve months later, the vendor pushes a silent algorithm update that meaningfully changes the model's outputs. No one on the clinical engineering or compliance team is alerted. The updated software is now operating under a different intended use than what was cleared—and from a regulatory standpoint, your organization has been running an unapproved medical device. This scenario is not hypothetical; it is the predictable outcome of applying hardware procurement logic to software that behaves like a living product.

As software-as-a-medical-device (SaMD) products—AI diagnostic tools, clinical decision support systems, remote patient monitoring algorithms, and autonomous analysis platforms—proliferate across every clinical specialty, they are arriving in procurement pipelines designed for centrifuges and infusion pumps, not adaptive machine-learning models. The FDA defines SaMD as software intended to